| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 40 | 2025 | 512 | 7.880 |
Why?
|
| Colonic Polyps | 14 | 2020 | 71 | 4.010 |
Why?
|
| Adenoma | 16 | 2019 | 96 | 3.100 |
Why?
|
| Gastrointestinal Diseases | 5 | 2021 | 51 | 2.220 |
Why?
|
| DNA Methylation | 10 | 2020 | 403 | 2.150 |
Why?
|
| Crocus | 8 | 2024 | 21 | 1.840 |
Why?
|
| Colonic Neoplasms | 9 | 2021 | 223 | 1.690 |
Why?
|
| Microsatellite Instability | 11 | 2024 | 48 | 1.490 |
Why?
|
| Colonoscopy | 14 | 2025 | 122 | 1.480 |
Why?
|
| Middle Aged | 56 | 2025 | 12222 | 1.340 |
Why?
|
| Aged | 41 | 2025 | 8214 | 1.260 |
Why?
|
| Humans | 93 | 2026 | 43102 | 1.240 |
Why?
|
| Male | 64 | 2025 | 23409 | 1.180 |
Why?
|
| Adenocarcinoma | 3 | 2025 | 291 | 1.150 |
Why?
|
| Female | 61 | 2025 | 24698 | 1.020 |
Why?
|
| Retrospective Studies | 17 | 2025 | 2544 | 1.010 |
Why?
|
| Health Status Disparities | 4 | 2021 | 719 | 0.980 |
Why?
|
| Promoter Regions, Genetic | 7 | 2020 | 526 | 0.970 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2024 | 863 | 0.950 |
Why?
|
| Liver Neoplasms | 2 | 2025 | 224 | 0.900 |
Why?
|
| Carcinoma | 3 | 2015 | 108 | 0.880 |
Why?
|
| Hospitalization | 3 | 2023 | 485 | 0.880 |
Why?
|
| Risk Factors | 20 | 2025 | 3994 | 0.880 |
Why?
|
| Diarrhea | 3 | 2022 | 95 | 0.870 |
Why?
|
| Ferritins | 2 | 2022 | 63 | 0.840 |
Why?
|
| Nutrigenomics | 1 | 2023 | 2 | 0.810 |
Why?
|
| Bacteria | 3 | 2021 | 293 | 0.780 |
Why?
|
| Mutation | 4 | 2019 | 1177 | 0.780 |
Why?
|
| Chromosome Aberrations | 2 | 2014 | 61 | 0.770 |
Why?
|
| Plant Extracts | 5 | 2024 | 302 | 0.720 |
Why?
|
| Hospital Mortality | 1 | 2023 | 210 | 0.720 |
Why?
|
| Dietary Supplements | 1 | 2023 | 213 | 0.700 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 13 | 0.680 |
Why?
|
| Enzymes | 1 | 2021 | 35 | 0.680 |
Why?
|
| Nausea | 1 | 2021 | 12 | 0.680 |
Why?
|
| Vomiting | 1 | 2021 | 14 | 0.680 |
Why?
|
| Lymph Nodes | 1 | 2021 | 74 | 0.670 |
Why?
|
| Abdominal Pain | 1 | 2021 | 24 | 0.670 |
Why?
|
| Condylomata Acuminata | 1 | 2020 | 6 | 0.670 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 186 | 0.670 |
Why?
|
| Prevalence | 12 | 2025 | 1612 | 0.660 |
Why?
|
| Adult | 33 | 2025 | 13872 | 0.660 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 37 | 0.660 |
Why?
|
| Anus Neoplasms | 1 | 2020 | 44 | 0.640 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 167 | 0.630 |
Why?
|
| Uterine Diseases | 1 | 2019 | 5 | 0.630 |
Why?
|
| Polyps | 1 | 2019 | 9 | 0.630 |
Why?
|
| Carotenoids | 2 | 2020 | 74 | 0.620 |
Why?
|
| Colon | 3 | 2021 | 120 | 0.620 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2019 | 24 | 0.610 |
Why?
|
| Interleukin-10 | 1 | 2020 | 87 | 0.610 |
Why?
|
| Spices | 1 | 2019 | 9 | 0.600 |
Why?
|
| Adenomatous Polyps | 2 | 2016 | 13 | 0.600 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 187 | 0.600 |
Why?
|
| Precancerous Conditions | 3 | 2016 | 83 | 0.580 |
Why?
|
| Risk Assessment | 6 | 2021 | 863 | 0.580 |
Why?
|
| Deinococcus | 4 | 2006 | 5 | 0.570 |
Why?
|
| Sequence Analysis, DNA | 3 | 2014 | 515 | 0.560 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2015 | 257 | 0.560 |
Why?
|
| Liver | 1 | 2021 | 511 | 0.540 |
Why?
|
| Receptors, Calcitriol | 2 | 2024 | 69 | 0.540 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 224 | 0.520 |
Why?
|
| Feces | 2 | 2016 | 132 | 0.510 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 704 | 0.510 |
Why?
|
| Case-Control Studies | 7 | 2024 | 1285 | 0.500 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2024 | 104 | 0.500 |
Why?
|
| Neoplasms | 3 | 2022 | 1377 | 0.490 |
Why?
|
| Helicobacter Infections | 2 | 2014 | 86 | 0.490 |
Why?
|
| Helicobacter pylori | 2 | 2014 | 118 | 0.480 |
Why?
|
| Colitis | 3 | 2021 | 71 | 0.480 |
Why?
|
| Smoking | 2 | 2020 | 1024 | 0.480 |
Why?
|
| Hospitals, University | 1 | 2015 | 39 | 0.470 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 376 | 0.470 |
Why?
|
| Receptor, EphA6 | 1 | 2015 | 2 | 0.460 |
Why?
|
| Genome, Human | 2 | 2014 | 144 | 0.450 |
Why?
|
| Prognosis | 5 | 2022 | 861 | 0.450 |
Why?
|
| United States | 19 | 2025 | 5205 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 760 | 0.450 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 223 | 0.450 |
Why?
|
| Aged, 80 and over | 12 | 2025 | 2853 | 0.450 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 9 | 0.440 |
Why?
|
| Prostatic Neoplasms | 2 | 2023 | 1092 | 0.430 |
Why?
|
| Genetic Variation | 1 | 2017 | 430 | 0.420 |
Why?
|
| Genetic Markers | 1 | 2014 | 150 | 0.400 |
Why?
|
| Neoplasm Staging | 5 | 2025 | 374 | 0.390 |
Why?
|
| Incidence | 9 | 2025 | 1078 | 0.380 |
Why?
|
| Chromosomes, Human, X | 1 | 2012 | 23 | 0.380 |
Why?
|
| Gene Amplification | 1 | 2012 | 23 | 0.380 |
Why?
|
| Comorbidity | 4 | 2023 | 737 | 0.360 |
Why?
|
| District of Columbia | 5 | 2021 | 80 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 734 | 0.350 |
Why?
|
| Butyrates | 1 | 2011 | 34 | 0.340 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 35 | 0.340 |
Why?
|
| CpG Islands | 3 | 2018 | 109 | 0.340 |
Why?
|
| Biological Products | 2 | 2023 | 91 | 0.340 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 100 | 0.340 |
Why?
|
| Young Adult | 8 | 2025 | 5080 | 0.330 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 71 | 0.330 |
Why?
|
| Cohort Studies | 8 | 2025 | 1759 | 0.320 |
Why?
|
| Iran | 4 | 2017 | 202 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 968 | 0.310 |
Why?
|
| Age Factors | 7 | 2025 | 1154 | 0.310 |
Why?
|
| Vitamin D | 1 | 2011 | 196 | 0.310 |
Why?
|
| Infant | 3 | 2021 | 1175 | 0.300 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 81 | 0.290 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2009 | 213 | 0.280 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 44 | 0.280 |
Why?
|
| Nuclear Proteins | 3 | 2009 | 333 | 0.270 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 440 | 0.270 |
Why?
|
| Odds Ratio | 5 | 2020 | 587 | 0.270 |
Why?
|
| Prospective Studies | 7 | 2025 | 1600 | 0.260 |
Why?
|
| Phylogeny | 4 | 2021 | 769 | 0.260 |
Why?
|
| Urban Health | 3 | 2015 | 101 | 0.250 |
Why?
|
| Toluene | 1 | 2006 | 11 | 0.250 |
Why?
|
| Child, Preschool | 2 | 2021 | 1546 | 0.250 |
Why?
|
| Chromium | 1 | 2006 | 28 | 0.250 |
Why?
|
| Adolescent | 6 | 2025 | 6081 | 0.240 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 28 | 0.240 |
Why?
|
| Hepatectomy | 1 | 2025 | 8 | 0.240 |
Why?
|
| Colectomy | 1 | 2025 | 24 | 0.230 |
Why?
|
| Olfaction Disorders | 1 | 2025 | 12 | 0.230 |
Why?
|
| Patient Compliance | 2 | 2019 | 233 | 0.230 |
Why?
|
| Delayed Diagnosis | 1 | 2025 | 38 | 0.230 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2025 | 8 | 0.220 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2024 | 187 | 0.220 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 638 | 0.220 |
Why?
|
| Patient Participation | 1 | 2026 | 94 | 0.220 |
Why?
|
| Dextran Sulfate | 2 | 2021 | 19 | 0.220 |
Why?
|
| Minority Groups | 2 | 2023 | 690 | 0.220 |
Why?
|
| Age of Onset | 1 | 2024 | 114 | 0.220 |
Why?
|
| Epigenesis, Genetic | 3 | 2018 | 291 | 0.220 |
Why?
|
| Aging | 2 | 2025 | 783 | 0.220 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 539 | 0.210 |
Why?
|
| DNA-Binding Proteins | 3 | 2023 | 561 | 0.210 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 310 | 0.210 |
Why?
|
| Genotype | 3 | 2024 | 800 | 0.210 |
Why?
|
| Chi-Square Distribution | 5 | 2015 | 236 | 0.210 |
Why?
|
| Crohn Disease | 2 | 2024 | 71 | 0.200 |
Why?
|
| Radioactive Waste | 1 | 2003 | 4 | 0.200 |
Why?
|
| Transcription Factors | 2 | 2020 | 735 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 220 | 0.200 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 15 | 0.200 |
Why?
|
| Logistic Models | 5 | 2020 | 1009 | 0.200 |
Why?
|
| Life Style | 2 | 2017 | 334 | 0.200 |
Why?
|
| Deoxyribonucleases | 2 | 2013 | 27 | 0.190 |
Why?
|
| Child | 2 | 2021 | 3443 | 0.190 |
Why?
|
| Computational Biology | 2 | 2017 | 327 | 0.190 |
Why?
|
| HCT116 Cells | 2 | 2021 | 40 | 0.190 |
Why?
|
| Metals | 1 | 2003 | 114 | 0.190 |
Why?
|
| Troponin | 1 | 2022 | 17 | 0.190 |
Why?
|
| Community-Based Participatory Research | 1 | 2026 | 352 | 0.180 |
Why?
|
| Haplotypes | 2 | 2020 | 197 | 0.180 |
Why?
|
| Alleles | 2 | 2020 | 352 | 0.180 |
Why?
|
| ras Proteins | 2 | 2014 | 54 | 0.180 |
Why?
|
| Trans-Activators | 2 | 2020 | 192 | 0.180 |
Why?
|
| Africa | 1 | 2021 | 82 | 0.180 |
Why?
|
| Cough | 1 | 2021 | 20 | 0.170 |
Why?
|
| Databases, Genetic | 2 | 2021 | 103 | 0.170 |
Why?
|
| Histones | 3 | 2013 | 197 | 0.170 |
Why?
|
| Latin America | 1 | 2020 | 55 | 0.170 |
Why?
|
| Occult Blood | 1 | 2020 | 32 | 0.170 |
Why?
|
| Fever | 1 | 2021 | 62 | 0.160 |
Why?
|
| Anal Canal | 1 | 2020 | 32 | 0.160 |
Why?
|
| Mice | 6 | 2023 | 6644 | 0.160 |
Why?
|
| Inflammation | 3 | 2022 | 758 | 0.160 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 449 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 179 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 290 | 0.160 |
Why?
|
| beta Catenin | 1 | 2020 | 78 | 0.160 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 70 | 0.150 |
Why?
|
| Colon, Ascending | 1 | 2019 | 3 | 0.150 |
Why?
|
| Colon, Sigmoid | 1 | 2019 | 4 | 0.150 |
Why?
|
| Colon, Transverse | 1 | 2019 | 5 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2020 | 69 | 0.150 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 436 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2020 | 161 | 0.150 |
Why?
|
| Rectum | 1 | 2019 | 27 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 101 | 0.150 |
Why?
|
| DNA, Viral | 1 | 2020 | 311 | 0.150 |
Why?
|
| Diet | 2 | 2023 | 826 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 163 | 0.140 |
Why?
|
| Cell Movement | 2 | 2020 | 655 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 238 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2024 | 518 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2019 | 259 | 0.140 |
Why?
|
| Animals | 8 | 2024 | 16992 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2020 | 195 | 0.140 |
Why?
|
| Sex Factors | 5 | 2025 | 1028 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2021 | 972 | 0.130 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 4 | 0.130 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 934 | 0.130 |
Why?
|
| Mass Screening | 2 | 2019 | 541 | 0.130 |
Why?
|
| Hepacivirus | 1 | 2017 | 74 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 67 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 1723 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 75 | 0.120 |
Why?
|
| Time Factors | 3 | 2017 | 1857 | 0.120 |
Why?
|
| Biopsy | 2 | 2014 | 177 | 0.120 |
Why?
|
| Fatty Liver | 1 | 2017 | 77 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 56 | 0.120 |
Why?
|
| Pancreatic Cyst | 1 | 2016 | 7 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1455 | 0.120 |
Why?
|
| Microarray Analysis | 2 | 2014 | 64 | 0.120 |
Why?
|
| Pathology, Clinical | 1 | 2015 | 4 | 0.120 |
Why?
|
| Demography | 2 | 2016 | 195 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 25 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2013 | 79 | 0.120 |
Why?
|
| Diverticulosis, Colonic | 1 | 2015 | 3 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2014 | 575 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 223 | 0.110 |
Why?
|
| Apoptosis | 2 | 2013 | 1568 | 0.110 |
Why?
|
| Endoscopy | 1 | 2014 | 17 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 37 | 0.110 |
Why?
|
| Mercury | 2 | 2006 | 39 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2020 | 925 | 0.110 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2014 | 23 | 0.110 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 32 | 0.110 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2014 | 7 | 0.110 |
Why?
|
| Obesity | 3 | 2021 | 1151 | 0.100 |
Why?
|
| Phenotype | 1 | 2017 | 780 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 122 | 0.100 |
Why?
|
| Gene Dosage | 1 | 2014 | 75 | 0.100 |
Why?
|
| Metagenomics | 1 | 2013 | 46 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 61 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 118 | 0.100 |
Why?
|
| DNA Helicases | 1 | 2013 | 48 | 0.100 |
Why?
|
| Oxidation-Reduction | 2 | 2006 | 457 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2013 | 37 | 0.100 |
Why?
|
| Endodeoxyribonucleases | 1 | 2012 | 28 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 2676 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2012 | 5 | 0.100 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 14 | 0.090 |
Why?
|
| DNA Fragmentation | 1 | 2012 | 98 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2012 | 37 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2014 | 2157 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 108 | 0.090 |
Why?
|
| Oman | 2 | 2008 | 7 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2023 | 260 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1019 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1063 | 0.090 |
Why?
|
| MutS Homolog 2 Protein | 3 | 2024 | 32 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 154 | 0.090 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2011 | 12 | 0.090 |
Why?
|
| Viral Load | 2 | 2025 | 348 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 249 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 386 | 0.090 |
Why?
|
| Seasons | 1 | 2011 | 139 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 165 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2012 | 383 | 0.080 |
Why?
|
| Puerto Rico | 2 | 2025 | 1413 | 0.080 |
Why?
|
| Chromosomal Instability | 1 | 2010 | 20 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2010 | 70 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2011 | 140 | 0.080 |
Why?
|
| Chromosomes, Human | 1 | 2010 | 37 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 1869 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2011 | 258 | 0.070 |
Why?
|
| Disease Progression | 3 | 2023 | 667 | 0.070 |
Why?
|
| Proteins | 1 | 2012 | 382 | 0.070 |
Why?
|
| Epithelial Cells | 2 | 2013 | 434 | 0.070 |
Why?
|
| Cytokines | 2 | 2024 | 678 | 0.070 |
Why?
|
| Proteomics | 1 | 2011 | 378 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2024 | 1003 | 0.070 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 61 | 0.070 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 36 | 0.070 |
Why?
|
| Genetics, Population | 1 | 2008 | 121 | 0.070 |
Why?
|
| Mesoderm | 1 | 2008 | 73 | 0.070 |
Why?
|
| STAT5 Transcription Factor | 1 | 2008 | 49 | 0.070 |
Why?
|
| Azacitidine | 2 | 2020 | 21 | 0.070 |
Why?
|
| Body Weight | 2 | 2021 | 429 | 0.070 |
Why?
|
| Gene Silencing | 2 | 2021 | 154 | 0.070 |
Why?
|
| Outpatients | 2 | 2019 | 37 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2013 | 661 | 0.060 |
Why?
|
| Intestinal Mucosa | 2 | 2021 | 134 | 0.060 |
Why?
|
| Geologic Sediments | 1 | 2006 | 46 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 3156 | 0.060 |
Why?
|
| Recombination, Genetic | 1 | 2006 | 95 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 355 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2025 | 45 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1596 | 0.060 |
Why?
|
| Smell | 1 | 2025 | 40 | 0.060 |
Why?
|
| Shewanella | 1 | 2005 | 5 | 0.060 |
Why?
|
| Independent Living | 1 | 2025 | 47 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 611 | 0.060 |
Why?
|
| Propensity Score | 1 | 2024 | 59 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 80 | 0.050 |
Why?
|
| Histocompatibility Antigens | 1 | 2023 | 12 | 0.050 |
Why?
|
| Water Pollutants, Chemical | 1 | 2006 | 171 | 0.050 |
Why?
|
| Bacterial Proteins | 2 | 2006 | 595 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2024 | 61 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2024 | 75 | 0.050 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2023 | 31 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2026 | 219 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2003 | 37 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 61 | 0.050 |
Why?
|
| Biodegradation, Environmental | 1 | 2003 | 82 | 0.050 |
Why?
|
| Virulence | 1 | 2024 | 246 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2006 | 460 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 113 | 0.050 |
Why?
|
| Prostate | 1 | 2023 | 155 | 0.050 |
Why?
|
| Histone Code | 1 | 2022 | 13 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 100 | 0.050 |
Why?
|
| Sirtuin 1 | 1 | 2022 | 34 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 313 | 0.050 |
Why?
|
| Retroelements | 1 | 2021 | 14 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 384 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 78 | 0.040 |
Why?
|
| Antioxidants | 1 | 2024 | 443 | 0.040 |
Why?
|
| Serotonin | 1 | 2021 | 123 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2020 | 19 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 152 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 25 | 0.040 |
Why?
|
| Interferons | 1 | 2020 | 40 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 298 | 0.040 |
Why?
|
| Interleukins | 1 | 2020 | 40 | 0.040 |
Why?
|
| Quality of Life | 1 | 2025 | 616 | 0.040 |
Why?
|
| Cathartics | 1 | 2019 | 6 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2021 | 456 | 0.040 |
Why?
|
| DNA | 1 | 2022 | 592 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 200 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 215 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 508 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 108 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2019 | 81 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 310 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 719 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2017 | 8 | 0.030 |
Why?
|
| Colombia | 1 | 2017 | 31 | 0.030 |
Why?
|
| Cell Survival | 1 | 2020 | 945 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 224 | 0.030 |
Why?
|
| Colonoscopes | 1 | 2016 | 2 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2021 | 1604 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 95 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 104 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2016 | 39 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 159 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 164 | 0.030 |
Why?
|
| Hypertension | 1 | 2021 | 835 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2013 | 33 | 0.030 |
Why?
|
| Hospitals | 1 | 2014 | 117 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 46 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 249 | 0.020 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Serine Proteases | 1 | 2012 | 3 | 0.020 |
Why?
|
| Cysteine Proteases | 1 | 2012 | 2 | 0.020 |
Why?
|
| Etoposide | 1 | 2012 | 21 | 0.020 |
Why?
|
| Gastroscopy | 1 | 2012 | 9 | 0.020 |
Why?
|
| Base Pairing | 1 | 2012 | 41 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2012 | 30 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 162 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 54 | 0.020 |
Why?
|
| Paneth Cells | 1 | 2012 | 3 | 0.020 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 22 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 296 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1271 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 161 | 0.020 |
Why?
|
| DNA Damage | 1 | 2013 | 356 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 437 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2013 | 363 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1234 | 0.020 |
Why?
|
| Calcium | 1 | 2012 | 491 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 883 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Genes, APC | 1 | 2009 | 15 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 107 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1067 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 95 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 609 | 0.020 |
Why?
|
| Mucins | 1 | 2008 | 73 | 0.020 |
Why?
|
| Culture Media | 1 | 2006 | 96 | 0.010 |
Why?
|
| Cadmium | 1 | 2006 | 56 | 0.010 |
Why?
|
| Cytosol | 1 | 2006 | 97 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 2005 | 13 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 2005 | 12 | 0.010 |
Why?
|
| Zinc | 1 | 2006 | 131 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2006 | 171 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 118 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 638 | 0.010 |
Why?
|
| Escherichia coli Proteins | 1 | 2006 | 133 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 671 | 0.010 |
Why?
|
| Manganese | 1 | 2005 | 92 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 403 | 0.010 |
Why?
|
| Iron | 1 | 2005 | 251 | 0.010 |
Why?
|
| HIV Infections | 1 | 2017 | 2586 | 0.010 |
Why?
|